CD34 and graft versus host disease: To decrease the incidence of GVHD in haploidentical allograft settings, the Perugia group established a protocol that includes TCD and a graft containing a mega-dose of highly purified CD34+ cells (average 10 × 106/kg body weight), which is administered following a myeloablative conditioning regimen (86).